{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:03:00Z","timestamp":1761742980966,"version":"3.33.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1007\/s11934-003-0013-3","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T20:23:54Z","timestamp":1181075034000},"page":"385-390","source":"Crossref","is-referenced-by-count":7,"title":["Update on overactive bladder: Pharmacologic approaches on the horizon"],"prefix":"10.1007","volume":"4","author":[{"given":"Eric S.","family":"Rovner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan J.","family":"Wein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"13_CR1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0022-5347(17)60721-3","volume":"108","author":"AC Diokno","year":"1972","unstructured":"Diokno AC, Lapides J: Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 1972, 108:307\u2013309.","journal-title":"J Urol"},{"key":"13_CR2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1464-410X.2000.00097.x","volume":"86","author":"ES Rovner","year":"2000","unstructured":"Rovner ES, Wein AJ: Modern pharmacotherapy of urge urinary incontinence in the U.S.: tolterodine and oxybutynin. Br J Urol 2000, 86:44\u201354.","journal-title":"Br J Urol"},{"key":"13_CR3","volume-title":"Campbell\u2019s Urology","author":"AJ Wein","year":"2002","unstructured":"Wein AJ: Neuromuscular dysfunction of the lower urinary tract and its management. In Campbell\u2019s Urology, edn 8. Edited by Walsh PC, Retik A, Vaughan ED Jr, et al. Philadelphia: WB Saunders; 2002.","edition":"edn 8"},{"key":"13_CR4","first-page":"447","volume-title":"Incontinence","author":"KE Andersson","year":"1999","unstructured":"Andersson KE, Appell RA, Cardozo L, et al.: Pharmacological treatment of urinary incontinence. In Incontinence. Edited by Abrams P, Khoury S, Wein AJ. Plymouth, UK: Heath Publication Ltd; 1999:447\u2013486."},{"key":"13_CR5","first-page":"CD003781","volume":"3","author":"J Hay-Smith","year":"2002","unstructured":"Hay-Smith J, Herbison P, Ellis G, Moore K: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2002, 3:CD003781.","journal-title":"Cochrane Database Syst Rev"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/S0022-5347(05)64261-9","volume":"168","author":"N Yoshimura","year":"2002","unstructured":"Yoshimura N, Chancellor MB: Current and future pharmacological treatment for overactive bladder. J Urol 2002, 168:1897\u20131913. This is a comprehensive review of many of the preclinical and clinical studies of potential pharmacologic therapies for overactive bladder. Included is an interesting discussion of future (theoretical) potential advances, including gene therapy.","journal-title":"J Urol"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/PL00007102","volume":"19","author":"DJ Sellers","year":"2001","unstructured":"Sellers DJ, Chapple CR, Chess-Williams R: Potential therapeutic targets for treatment of the overactive bladder. World J Urol 2001, 19:307\u2013311.","journal-title":"World J Urol"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0302-2838(01)00009-4","volume":"41","author":"ES Rovner","year":"2002","unstructured":"Rovner ES, Wein AJ: Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002, 41:6\u201314.","journal-title":"Eur Urol"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","volume":"57","author":"P Kerrebroeck Van","year":"2001","unstructured":"Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine oncedaily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001, 57:414\u2013421.","journal-title":"Urology"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","volume":"16","author":"RU Anderson","year":"1999","unstructured":"Anderson RU, Mobley D, Blank B, et al.: Once-daily controlled versus immediate-release oxybutynin chloride for urge incontinence. J Urol 1999, 16:1809\u20131812.","journal-title":"J Urol"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/009127009903900313","volume":"39","author":"SK Gupta","year":"1999","unstructured":"Gupta SK, Sathyan G: Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999, 39:289\u2013296.","journal-title":"J Clin Pharmacol"},{"key":"13_CR12","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-5347(01)62828-3","volume":"160","author":"G Buyse","year":"1998","unstructured":"Buyse G, Waldeck K, Verpoorten C, et al.: Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998, 160:892\u2013896.","journal-title":"J Urol"},{"key":"13_CR13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00498259209053145","volume":"22","author":"KM Hughes","year":"1992","unstructured":"Hughes KM, Lang JC, Lazare R, et al.: Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992, 22:859\u2013869.","journal-title":"Xenobiotica"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0022-5347(01)65148-6","volume":"157","author":"K Waldeck","year":"1997","unstructured":"Waldeck K, Larsson B, Andersson KE: Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997, 157:1093\u20131097.","journal-title":"J Urol"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(05)66095-8","volume":"166","author":"GW Davila","year":"2001","unstructured":"Davila GW, Daugherty CA, Sanders SW, et al.: A short-term, multicenter, randomized, double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001, 166:140\u2013145. Represents the initial peer-reviewed publications on the use of transdermal antimuscarinic therapy for overactive bladder.","journal-title":"J Urol"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0022-5347(05)64684-8","volume":"168","author":"RR Dmochowski","year":"2002","unstructured":"Dmochowski RR, Davila GW, Zinner NR, et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002, 168:580\u2013586. Represents the initial peer-reviewed publications on the use of transdermal antimuscarinic therapy for overactive bladder.","journal-title":"J Urol"},{"key":"13_CR17","first-page":"380","volume":"21","author":"R Dmochowski","year":"2002","unstructured":"Dmochowski R, Davila W, Sanders S: Transdermal oxybutynin and controlled release oral tolterodine in patients with positive treatment effect to anticholinergic therapy for overactive bladder. Neurourol Urodyn 2002, 21:380\u2013381.","journal-title":"Neurourol Urodyn"},{"key":"13_CR18","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0022-5347(17)41304-8","volume":"141","author":"CB Brendler","year":"1989","unstructured":"Brendler CB, Radebaugh LC, Mohler JL: Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989, 141:1350\u20131352.","journal-title":"J Urol"},{"key":"13_CR19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1464-410X.1993.tb16210.x","volume":"723","author":"KJ O\u2019Flynn","year":"1993","unstructured":"O\u2019Flynn KJ, Thomas DG: Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia. Br J Urol 1993, 723:566\u2013570.","journal-title":"Br J Urol"},{"key":"13_CR20","first-page":"252","volume":"165","author":"TB Boone","year":"2001","unstructured":"Boone TB, Appell RA, Lopez MA, et al.: Pharmacokinetics evaluation of intravesical oxybutynin: bolus and continuous delivery. J Urol 2001, 165:252\u2013253.","journal-title":"J Urol"},{"key":"13_CR21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00191165","volume":"47","author":"A Pietzko","year":"1994","unstructured":"Pietzko A, Dimpfel W, Schwantes U, Topfmeier P: Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994, 47:337\u2013343.","journal-title":"Eur J Clin Pharmacol"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s003450100225","volume":"19","author":"K Hofner","year":"2001","unstructured":"Hofner K, Oelke M, Machtens S, Grunewald V: Trospium chloride: an effective drug in the treatment of overactive bladder and detrusor hyper-reflexia. World J Urol 2001, 19:336\u2013343. This is a well-written summary of the up-to-date clinical studies on trospium.","journal-title":"World J Urol"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.bjp.0703068","volume":"129","author":"MH Hawthorn","year":"2000","unstructured":"Hawthorn MH, Chapple CR, Cock M, Chess-Williams R: Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 2000, 129:416\u2013419.","journal-title":"Br J Pharmacol"},{"key":"13_CR24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1464-410x.2000.00575.x","volume":"85","author":"L Cardozo","year":"2000","unstructured":"Cardozo L, Chapple CR, Toozs-Hobson P, et al.: Efficacy of trospium chloride in patient with detrusor instability: a placebo-controlled, randomized, double blind, multicentre clinical trial. BJU Int 2000, 85:659\u2013664.","journal-title":"BJU Int"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000282207","volume":"47","author":"M Stohrer","year":"1991","unstructured":"Stohrer M, Bauer P, Giannetti BM, et al.: Effect of trospium chloride on urodynamic parameters n patients with detrusor hyper-reflexia due to spinal cord injuries: a multicentre, placebo-controlled, double-blind trial. Urol Int 1991, 47:138\u2013143.","journal-title":"Urol Int"},{"key":"13_CR26","first-page":"439","volume":"1","author":"S Alloussi","year":"1998","unstructured":"Alloussi S, Laval KU, Eckert R, et al.: Trospium chloride in a patient with motor urge syndrome (detrusor instability): a double-blind, randomized, multicentre, placebo-controlled study. J Clin Res Drug Dev 1998, 1:439\u2013451.","journal-title":"J Clin Res Drug Dev"},{"key":"13_CR27","first-page":"487","volume":"19","author":"K Hofner","year":"2000","unstructured":"Hofner K, Halaska M, Primus G, et al.: Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge syndrome: a double-blind, controlled, multicentre clinical trial. Neurourol Urodyn 2000, 19:487\u2013488.","journal-title":"Neurourol Urodyn"},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/bmj.315.7119.1363","volume":"315","author":"CA Donnellan","year":"1997","unstructured":"Donnellan CA, Fook L, McDonald P, Playfer JR: Oxybutynin and cognitive dysfunction. BMJ 1997, 315:1363\u20131364.","journal-title":"BMJ"},{"key":"13_CR29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","volume":"46","author":"IR Katz","year":"1998","unstructured":"Katz IR, Sands LP, Bilker W, et al.: Identification of medications that can cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998, 46:8\u201313.","journal-title":"J Am Geriatr Soc"},{"key":"13_CR30","first-page":"555","volume":"14","author":"DT Newgreen","year":"1995","unstructured":"Newgreen DT, Anderson DW, Carter AJ, et al.: Darifenacin: a novel bladder-selective agent for the treatment of urge incontinence. Neurourol Urodyn 1995, 14:555\u2013557.","journal-title":"Neurourol Urodyn"},{"key":"13_CR31","first-page":"36","volume":"165","author":"AS Braverman","year":"2001","unstructured":"Braverman AS, Ruggieri MR, Pontari MA: The M2 muscarinic receptor subtype mediates cholinergic bladder contractions in patients with neurogenic bladder dysfunction. J Urol 2001, 165:36.","journal-title":"J Urol"},{"key":"13_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/ajpregu.00116.2002","volume":"283","author":"AS Braverman","year":"2002","unstructured":"Braverman AS, Tallarida RJ, Ruggieri MR: Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction. Am J Physiol Regul Integr Comp Physiol 2002, 283:1\u20136.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"13_CR33","first-page":"240","volume":"30","author":"DJ Rosario","year":"1996","unstructured":"Rosario DJ, Cutinha PE, Chapple CR: The effects of single-dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability. Eur Urol 1996, 30:240.","journal-title":"Eur Urol"},{"key":"13_CR34","first-page":"381","volume":"21","author":"CR Chapple","year":"2002","unstructured":"Chapple CR, Arano P, Bosch JH, et al.: YM 905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo and tolterodine controlled phase II dose finding study. Neurourol Urodyn 2002, 21:381\u2013382.","journal-title":"Neurourol Urodyn"},{"key":"13_CR35","first-page":"532","volume":"20","author":"P Norton","year":"2001","unstructured":"Norton P, Zinner N, Yalcin I, et al.: Duloxetine versus placebo in the treatment of stress urinary incontinence. Neurourol Urodyn 2001, 20:532\u2013534.","journal-title":"Neurourol Urodyn"},{"key":"13_CR36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0006-8993(82)90865-4","volume":"234","author":"SB MacMahon","year":"1982","unstructured":"MacMahon SB, Spillane K: Brain stem influences on the parasympathetic supply to the urinary bladder of the cat. Brain Res 1982, 234:237\u2013249.","journal-title":"Brain Res"},{"key":"13_CR37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0014-2999(95)00614-1","volume":"287","author":"MJ Espey","year":"1995","unstructured":"Espey MJ, Downie JW: Serotonergic modulation of cat bladder function before and after spinal transection. Eur J Pharmacol 1995, 287:173\u2013177.","journal-title":"Eur J Pharmacol"},{"key":"13_CR38","first-page":"1014","volume":"274","author":"KB Thor","year":"1995","unstructured":"Thor KB, Katofiasc MA: Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995, 274:1014\u20131024.","journal-title":"J Pharmacol Exp Ther"},{"key":"13_CR39","first-page":"383","volume":"21","author":"N Zinner","year":"2002","unstructured":"Zinner N, Dmochowski R, Miklos J, et al.: Duloxetine versus placebo in the treatment of stress urinary incontinence (SUI). Neurourol Urodyn 2002, 21:383\u2013384.","journal-title":"Neurourol Urodyn"},{"key":"13_CR40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","volume":"164","author":"B Schurch","year":"2000","unstructured":"Schurch B, Stohrer M, Kramer G, et al.: Botulinum-A toxin for treating detrusor hyper-reflexia in spinal cord injured patients: A new alternative to anticholinergic drug? Preliminary report. J Urol 2000, 164:692\u2013697.","journal-title":"J Urol"},{"key":"13_CR41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0090-4295(01)01635-1","volume":"59","author":"O Yamaguchi","year":"2002","unstructured":"Yamaguchi O: _3 Adrenoreceptors in human detrusor muscle. Urology 2002, 59:25\u201329.","journal-title":"Urology"},{"key":"13_CR42","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0022-3565(24)38094-2","volume":"288","author":"M Takeda","year":"1999","unstructured":"Takeda M, Obara K, Mizusawa T, et al.: Evidence for _3 adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 1999, 288:1367\u20131373.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-003-0013-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-003-0013-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-003-0013-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T23:52:04Z","timestamp":1737071524000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-003-0013-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s11934-003-0013-3","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"type":"print","value":"1527-2737"},{"type":"electronic","value":"1534-6285"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}